Search Results - "Che, Mandy"

Screening for PTSD during pregnancy: a missed opportunity by Padin, Avelina C, Stevens, Natalie R, Che, Mandy L, Erondu, Ihuoma N, Perera, Marisa J, Shalowitz, Madeleine U

“…Prenatal posttraumatic stress disorder (PTSD) is often overlooked in obstetric care, despite evidence that untreated PTSD negatively impacts both mother and…”
Get full text

Incorporation of Patient‐Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center by Matthys, Madeline B., Dempsey, Andre M., Melisko, Michelle E., Dreher, Nickolas, Che, Mandy L., Veer, Laura J., Esserman, Laura J., Basu, Amrita

“…Background Symptom burden and reduced quality of life (QOL) are considerable hurdles in oncology. The authors used the Patient‐Reported Outcomes Measurement…”
Get full text

Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study by Wang, Tianyi, Che, Mandy, Huilgol, Yash S., Keane, Holly, Goodman, Deborah, Soonavala, Rashna, Ozanne, Elissa, Shieh, Yiwey, Belkora, Jeffrey K., Fiscalini, Allison Stover, Esserman, Laura J.

“…Breast cancer risk reduction strategies have been well-validated, but barriers remain for high-risk individuals to adopt them. We performed a study among…”
Get full text

Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial by Keane, Holly, Huilgol, Yash S., Shieh, Yiwey, Tice, Jeffrey A., Belkora, Jeff, Sepucha, Karen, Shibley, W. Patrick, Wang, Tianyi, Che, Mandy, Goodman, Deborah, Ozanne, Elissa, Fiscalini, Allison Stover, Esserman, Laura J.

“…Breast cancer risk reduction has been validated by large-scale clinical trials, but uptake remains low. A risk communication tool could provide personalized…”
Get full text

Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry by Huilgol, Yash S., Keane, Holly, Shieh, Yiwey, Hiatt, Robert A., Tice, Jeffrey A., Madlensky, Lisa, Sabacan, Leah, Fiscalini, Allison Stover, Ziv, Elad, Acerbi, Irene, Che, Mandy, Anton-Culver, Hoda, Borowsky, Alexander D., Hunt, Sharon, Naeim, Arash, Parker, Barbara A., van ‘T Veer, Laura J., Esserman, Laura J.

“…Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast…”
Get full text

Abstract PS7-43: Validation study results for a personalized prevention education aid in breast cancer risk reduction by Wang, Tianyi, Che, Mandy, Huilgol, Yash, Goodman, Deborah, Keane, Holly, Lee, Vivian, Belkora, Jeff, Fiscalini, Allison, Esserman, Laura

“…BackgroundOptions for breast cancer risk reduction include endocrine medications (tamoxifen, raloxifene, aromatase inhibitors) and lifestyle modifications…”
Get full text

Abstract P5-08-01: Breast cancer risk thresholds as a predictor of chemoprevention uptake in the Athena Breast Health Network by Huilgol, Yash S, Keane, Holly, Shieh, Yiwey, Tice, Jeffrey, Ziv, Elad, Madlensky, Lisa, Sabacan, Leah, Acerbi, Irene, Che, Mandy, Fiscalini, Allison Stover, Anton-Culver, Hoda, Borowsky, Alexander D, Hunt, Sharon, Naeim, Arash, Parker, Barbara, van 't Veer, Laura J

“…Background: Large-scale chemoprevention trials validated endocrine risk reduction strategies to lower breast cancer risk. We sought to understand the risk at…”
Get full text

Abstract OT-22-01: Opportunities and lessons learned in using electronic health record patient portal (MyChart) for recruitment to the population-based WISDOM study by Petruse, Antonio, Rocha, Alyssa, Johansen, Liliana, Wenger, Neil, Che, Mandy, Fors, Steele, Park, Hannah L, Wernisch, Janet, Acerbi, Irene, Fiscalini, Allison S, Hassam, Jasmin, LaCroix, Andrea, Parker, Barbara, Madlensky, Lisa, Van't Veer, Laura, Kaplan, Celia, Anton-Culver, Hoda, Kaster, Andrea, Stewart, Skye, Rouf, Samrrah, Borowsky, Alexander, Hurley, Ian, Hiatt, Robert, Lee, Vivian, Heditsian, Diane, Brain, Susie, Olopade, Olufunmilayo, Sheth, Deepa, Esserman, Laura, Naeim, Arash

“…Background: WISDOM is a preference-tolerant, pragmatic study comparing annual mammogram screening to personalized, risk-based breast screening in healthy women…”
Get full text

Abstract OT-21-01: Personalized breast cancer screening in a population-based study: Women informed to screen depending on measures of risk (WISDOM) by Acerbi, Irene, Fiscalini, Allison Stover, Che, Mandy, Shieh, Yiwey, Madlensky, Lisa, Tice, Jeffrey, Ziv, Elad, Eklund, Martin, Blanco, Amie, Tong, Barry, Goodman, Deborah, Nassereddine, Lamees, Anderson, Nancy, Harvey, Heather, Fors, Steele, Park, Hannah L, Petruse, Antonia, Stewart, Skye, Wernisch, Janet, Risty, Larissa, Hurley, Ian, Koenig, Barbara, Kaplan, Celia, Hiatt, Robert, Wenger, Neil, Lee, Vivian, Heditsian, Diane, Brain, Susie, Sabacan, Leah, Wang, Tianyi, Parker, Barbara A, Borowsky, Alexander, Anton-Culver, Hoda, Naeim, Arash, Kaster, Andrea, Talley, Melinda, van 't Veer, Laura, LaCroix, Andrea Z, Olopade, Olufunmilayo I, Sheth, Deepa, Garcia, Augustin, Lancaster, Rachel, Esserman, Laura

“…Background: WISDOM is a 100,000 healthy women preference-tolerant, pragmatic study comparing traditional annual screening to personalized risk-based breast…”
Get full text

Abstract OT3-03-02: Personalized breast cancer screening in a population-based study: Women informed to screen depending on measures of risk (WISDOM) by Che, Mandy, Fiscallini, Allison Stover, Acerbi, Irene, Shieh, Yiweh, Madlensky, Lisa, Tice, Jeffrey, Ziv, Elad, Eklund, Martin, Blanco, Amie, Tong, Barry, Goodman, Deborah, Nassereddine, Lamees, Anderson, Nancy, Harvey, Heather, Fors, Steele, Park, Hannah L, Petruse, Antonia, Stewart, Skye, Wernisch, Janet, Risty, Larissa, Hurley, Ian, Koenig, Barbara, Kaplan, Celia, Hiatt, Robert, Wenger, Neil, Lee, Vivian, Heditsian, Diane, Brain, Susie, Sabacan, Leah, Parker, Barbara, Borowsky, Alexander, Anton-Culver, Hoda, Naeim, Arash, Kaster, Andrea, Talley, Melinda, van't Veer, Laura, LaCroix, Andrea, Olopade, Olufunmilayo I, Sheth, Deepa

“…Background: WISDOM is a 100,000 healthy women preference-tolerant, pragmatic study comparing traditional annual screening to personalized risk-based breast…”
Get full text